Navigation Links
Study of HIV increase in Pakistan could benefit other research
Date:8/24/2011

GAINESVILLE, Fla. Rates of HIV have increased in Pakistan's general population, as the virus has spread beyond at-risk groups to women and their children, according to an international team of researchers, including a University of Florida scientist.

The researchers raise concern that the transmission across subgroups into Pakistan's general population may serve as indication that the virus may be spreading into populations within neighboring Afghanistan. The team's epidemiological findings were published in July in the journal PLoS One.

The technique used to understand the forces that drive the HIV epidemic in Pakistan could also help health care professionals understand and intervene in other deadly disease outbreaks wherever they occur, researchers say.

"Are the strains in Pakistan and Afghanistan of two different epidemic origins, or are they the same? It's an important question," said paper author Marco Salemi, a UF College of Medicine professor and a member of the UF Emerging Pathogens Institute and the UF Genetics Institute. "Genetic evidence can be used to test how different populations are intersecting. As you can imagine, behavioral data is difficult to get in some countries and this is why molecular tools are important."

Salemi analyzed DNA sequences of blood samples from three HIV-positive groups: intravenous drug users, men who have sex with men, and women who have become infected by their bisexual spouses. By examining the evolutionary makeup of HIV strains, scientists say one of the strongest factors of the disease's spread is through men who sleep with male intravenous drug users.

The study was led by scientists at Aga Khan University and Dow University of Health Sciences, both in Karachi, Pakistan's capital, and the team is part of a larger consortium of researchers worldwide who have published in the last year, further documenting the spread of HIV in predominantly Muslim countries. The scientists say they will continue the epidemiological work in Afghanistan.

Deriving information from molecular studies is also essential to complement information that may not necessarily be accurate, or truthful, from in-person interviews.

"These questions are very sensitive and most of the behaviors we deal with, even in countries outside the Middle East, are illegal behaviors," said Willi McFarland, director of the HIV Epidemiology Section at the San Francisco Department of Public Health.

McFarland is an author of a PLoS One paper that also appeared this summer. That research was led by scientists from the Qatar branch of Weill Cornell Medical College who examined smaller studies from the Middle East and North Africa of men who hid their sexuality out of fear of prosecution.

Despite certain social and legal limitations that may make conducting similar studies difficult in some parts of the world, McFarland says the trust and confidentiality established between physicians and their patients proved crucial in providing the demographic information needed to conduct international studies such as these.

"Despite the legal consequences, the doctor patient-relationship does seem to be respected," McFarland said.


'/>"/>

Contact: Marco Salemi
salemi@pathology.ufl.edu
352-273-9567
University of Florida
Source:Eurekalert

Related medicine news :

1. Unintended Pregnancies Rising Among Poorer U.S. Women: Study
2. Study: 85 percent of homeless people have chronic health conditions
3. Nurses at Risk for Accidental Exposure to Chemo Drugs: Study
4. Boys Mature Sexually Earlier Than Ever Before: Study
5. Women With Heart Failure Treated as Well as Men: Study
6. Injectable Psoriasis Drugs May Not Hike Heart Risks: Study
7. Mental Illness Affects Women, Men Differently, Study Finds
8. Study: Afghan patients a common source of drug-resistant bacteria
9. Study Links Writing Difficulties to ADHD
10. Most Heart Attack Patients Who Need Angioplasty Quickly Get It: Study
11. Study finds shifting domestic roles for men who lost jobs in current recession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September 20, 2017 , ... ... date of the much-anticipated fall event , Look Awesome This Autumn with ... personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that Clear Global ... support services market) has entered into an agreement on September 1, 2017 with ... PGSD is the first private Dental School to launch an online, accredited Post ...
(Date:9/20/2017)... ... , ... Compliancy Group is proud to announce that its ... another long-time client pass their Department of Health and Human Services (HHS) Office ... to the help of the Compliancy Group's Audit Response Program™, not a single ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods ... market impact in 27 different categories. Nopavera Plus was named to the ... be announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: